RMTG Q1 revenue up 90% YoY, Q2 quadrupled; Argentina license, Cancun lab expansion

Regenerative Medical Technology Group Inc.

Q1 2026 revenue up 90% YoY; Q2 revenue quadrupled YoY; 2025 total revenue $5.1M.
Argentina granted first-ever license to harvest/produce biologics; Cancun lab added 2 clean rooms with COFEPRIS sign-off.
ISSCA AI launched with 30 years of 60M redacted patient records to power physician tool.
BKFC partnership continues; fighter Ben Rothwell treated; more announcements expected.
Company evaluating capital raising strategies; may increase authorized shares; Nasdaq uplisting desired but no timeline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.